NURECA - Nureca
📢 Recent Corporate Announcements
Nureca Limited's promoter group has seen their collective shareholding increase from 64.97% to 68.09%. This change is a direct result of the company's recent buyback program, which concluded with the extinguishment of 4,58,255 equity shares on January 07, 2026. While the absolute number of shares held by the promoters remained unchanged at 64,97,176, the reduction in the total share capital base led to a 3.12% increase in their voting rights. This transaction is exempt from open offer requirements under SEBI (SAST) Regulation 10(4)(c).
- Promoter group stake increased by 3.12% to reach a total of 68.09% of the company.
- Total equity share capital reduced from 1,00,00,175 to 95,41,920 shares post-extinguishment.
- A total of 4,58,255 shares, representing approximately 4.58% of the pre-buyback capital, were extinguished.
- Individual promoter Saurabh Goyal's stake increased from 32.17% to 33.72% without purchasing new shares.
- The disclosure was filed under Regulation 10(6) of SEBI (SAST) Regulations, 2011.
Nureca Limited reported a strong financial performance for Q3 FY26, with revenue growing 27% YoY to INR 540 Mn. The company achieved a significant turnaround in profitability, posting a PAT of INR 37 Mn compared to a loss of INR 28 Mn in the same quarter last year. EBITDA saw a massive 314% YoY jump to INR 54 Mn, reflecting improved operational efficiency and a 10% margin. The company remains debt-free and continues to derive over 90% of its revenue from digital channels, supported by a cumulative customer base of 17.5 million.
- Q3 FY26 Revenue grew 27% YoY to INR 540 Mn; 9M FY26 revenue reached INR 1,536 Mn.
- PAT turned positive at INR 37 Mn in Q3 FY26, a 233% increase from a loss of INR 28 Mn in Q3 FY25.
- EBITDA for Q3 FY26 stood at INR 54 Mn (10% margin) compared to INR 25.4 Mn in the previous year.
- The company is debt-free with a healthy current ratio of 9.6 and a cumulative customer base of 17.5 million.
- Digital-first strategy remains dominant with over 90% of revenue generated through online sales.
Nureca Limited reported a strong Q3 FY26 with revenue increasing 27% YoY to INR 540 Mn and a significant turnaround in profitability, posting a PAT of INR 37 Mn compared to a loss in the previous year. The company continues to dominate the digital healthcare space with over 90% of revenue generated through online sales and a cumulative customer base of 17.5 million. EBITDA grew substantially to INR 54 Mn, reflecting a 113% increase over the previous year's quarter. The company remains debt-free with a healthy liquidity position, although its new manufacturing site in Punjab faces delays due to statutory approvals.
- Revenue for Q3 FY26 grew 27% YoY to INR 540 Mn, while 9M FY26 revenue reached INR 1,536 Mn.
- Achieved a PAT of INR 37 Mn in Q3 FY26, a sharp recovery from a loss of INR 28 Mn in Q3 FY25.
- Gross Profit surged 50% YoY to INR 396 Mn, driven by strong brand equity of 'Dr Trust' and digital-first efficiency.
- Maintains a debt-free balance sheet with a cumulative customer base of 17.5 million users.
- New manufacturing facility at Sundran, Punjab is currently delayed pending statutory approvals.
Nureca Limited reported a strong Q3 FY26 with revenue rising 50% YoY to ₹39.6 crore. The company successfully turned around its bottom line, posting a PAT of ₹3.7 crore against a loss of ₹2.8 crore in Q3 FY25. For the 9M FY26 period, revenue grew 43% to ₹111.6 crore, and PAT surged 604% to ₹8.2 crore. This performance was driven by sourcing efficiencies, cost optimization, and improved manufacturing capabilities.
- Q3 FY26 Revenue grew 50% YoY to ₹39.6 crore compared to ₹26.5 crore in Q3 FY25
- Operating profit for Q3 FY26 stood at ₹3.3 crore, a 181% recovery from a loss of ₹4.0 crore
- 9M FY26 PAT increased by 604% YoY to ₹8.2 crore from a loss of ₹1.6 crore
- Sequential revenue growth was 5% QoQ, indicating steady momentum
- Management highlights cost optimization and supply chain controls as key margin drivers
Nureca Limited reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 57.3% YoY to ₹416.22 million. The company's consolidated profit after tax increased to ₹37.34 million from ₹28.01 million in the same quarter last year. On a standalone basis, the company achieved a significant turnaround, posting a profit of ₹32.31 million compared to a loss of ₹32.89 million in Q3FY25. Additionally, the company successfully completed a share buyback worth ₹19.14 crore at ₹330 per share during the quarter.
- Consolidated revenue from operations surged 57.3% YoY to ₹416.22 million in Q3FY26.
- Consolidated PAT grew by 33.3% YoY to ₹37.34 million, with EPS rising to ₹3.91 from ₹2.80.
- Standalone results showed a major turnaround with a profit of ₹32.31 million vs a loss of ₹32.89 million YoY.
- Completed a ₹19.14 crore buyback at ₹330 per share, resulting in the extinguishment of shares during the quarter.
- Ongoing merger with subsidiary Nureca Technologies Private Limited is set for an effective date of April 1, 2025.
Nureca Limited reported a strong performance for Q3 FY26, with consolidated revenue from operations growing 39.3% YoY to ₹39.64 crore. Net profit for the quarter stood at ₹3.73 crore, a significant improvement from ₹2.80 crore in the same period last year. For the nine-month period, the company turned profitable with a PAT of ₹8.16 crore compared to a loss of ₹1.62 crore in 9M FY25. Additionally, the company successfully completed a share buyback worth ₹19.14 crore at ₹330 per share during the quarter.
- Consolidated Revenue from operations increased to ₹39.64 crore in Q3 FY26 from ₹28.46 crore in Q3 FY25.
- Net Profit (PAT) grew 33.3% YoY to ₹3.73 crore, with EPS rising to ₹3.91 from ₹2.80.
- 9M FY26 performance showed a sharp turnaround with a profit of ₹8.16 crore vs a loss of ₹1.62 crore in the previous year.
- Successfully completed a buyback of equity shares worth ₹19.14 crore at a price of ₹330 per share.
- Ongoing merger process of wholly-owned subsidiary Nureca Technologies Private Limited to streamline operations.
Nureca Limited has responded to NSE's clarification request regarding discrepancies in its XBRL filings for the quarter ended September 30, 2025. The company corrected a reporting error where the quarter was inadvertently labeled as 'Half-Yearly' in the digital filing. Financially, while standalone revenue for Q2 FY26 dropped significantly to ₹140.27 million from ₹337.07 million YoY, the company achieved a turnaround in profitability, posting a PAT of ₹31.40 million compared to a loss of ₹5.51 million in the same period last year. The company is also streamlining operations by merging one subsidiary and striking off another.
- Corrected XBRL filing error where reporting type was mistakenly selected as Half-Yearly instead of Quarterly.
- Standalone Q2 FY26 Revenue from Operations fell 58% YoY to ₹140.27 million.
- Turned profitable with a Standalone Net Profit of ₹31.40 million vs a loss of ₹5.51 million in Q2 FY25.
- Standalone EPS improved to ₹3.14 for the quarter from a negative ₹0.55 YoY.
- Ongoing corporate restructuring includes the merger of Nureca Technologies and striking off of Nureca Healthcare.
Nureca Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the period ending December 31, 2025. The company's Registrar and Share Transfer Agent, Alankit Assignments Limited, confirmed that zero dematerialization requests were received during the quarter. Notably, the report states that 100% of the company's shareholders are already in electronic mode, with no physical shareholders remaining. This is a standard regulatory filing confirming administrative compliance.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Zero dematerialization requests were processed during the three-month period.
- RTA confirms that all shareholders of Nureca Limited are in electronic mode.
- The filing adheres to SEBI (Depositories and Participants) Regulations, 2018 requirements.
Nureca Limited has successfully completed the extinguishment of 4,58,255 equity shares following its buyback via the tender offer route. The buyback was executed at a price of ₹330 per share, leading to a reduction in the total paid-up equity share capital by approximately 4.58%. Post-extinguishment, the total number of equity shares stands reduced at 95,41,920 from the previous 1,00,00,175 shares. This corporate action is now fully concluded in compliance with SEBI Buyback Regulations.
- Extinguished 4,58,255 equity shares of face value ₹10 each on January 7, 2026.
- The buyback was conducted at a price of ₹330 per share through a tender offer mechanism.
- Total paid-up equity share capital decreased from ₹10.00 crore to ₹9.54 crore.
- The total number of outstanding equity shares reduced from 1,00,00,175 to 95,41,920.
- The buyback tendering period was open from December 18, 2025, to December 24, 2025.
Nureca Limited has been issued formal warning letters by both BSE and NSE for failing to comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations. The company did not conduct any meeting of its Stakeholders Relationship Committee during the entire Financial Year 2024-25, violating Regulation 20(3A). While the company reports no immediate financial impact, the exchanges have warned that future lapses will be viewed seriously and could lead to further disciplinary action. The board is now required to review these warnings and implement corrective measures to ensure future compliance.
- Received warning letters from BSE on January 06, 2026, and NSE on January 07, 2026.
- Non-compliance identified regarding Regulation 20(3A) of SEBI LODR for FY 2024-25.
- Zero meetings of the Stakeholders Relationship Committee were held during the specified financial year.
- Exchanges have advised the company to exercise due caution and initiate corrective steps immediately.
- Company states there is no quantifiable monetary impact on financial or operational activities currently.
Nureca Limited has issued a post-buyback public announcement following the completion of its share repurchase program via the tender offer route. The company bought back equity shares for an aggregate amount not exceeding ₹19.14 crores at a maximum price of ₹330 per share. The buyback process, managed by Mefcom Capital Markets Limited, followed the board's approval on November 28, 2025. This announcement marks the formal conclusion of the buyback exercise as per SEBI regulations.
- Maximum buyback size of ₹19,14,00,000 (₹19.14 crores) excluding transaction costs.
- Buyback price set at a maximum of ₹330 per equity share with a face value of ₹10.
- The offer was executed through the tender offer mechanism via the stock exchange.
- Post-buyback public announcement was published on January 01, 2026, in major national newspapers.
- Mefcom Capital Markets Limited acted as the Manager to the Buyback Offer.
Nureca Limited has informed the stock exchanges that its trading window for dealing in equity shares will be closed starting January 1, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of the company's un-audited financial results for the third quarter ending December 31, 2025. The restriction applies to all designated persons and their immediate relatives. The window will remain closed until 48 hours after the financial results are officially announced.
- Trading window closure effective from January 01, 2026.
- Closure is related to the un-audited financial results for the quarter ending December 31, 2025.
- Window to reopen 48 hours after the official declaration of Q3 results.
- Prohibition applies to all designated persons and their immediate relatives as per SEBI norms.
Nureca Limited has announced a change in its registered office address within the city of Mumbai. The office has moved from Goregaon East to Andheri West, effective from December 10, 2025. This relocation was conducted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is a routine administrative update and does not affect the company's business operations or financial performance.
- Registered office relocated from Goregaon East, Mumbai to Andheri West, Mumbai.
- The change is officially effective from Wednesday, December 10, 2025.
- New address is B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Mumbai - 400053.
- The move was communicated to both BSE and NSE as per regulatory requirements.
Nureca Limited announced that its wholly-owned subsidiary, Nureca Healthcare Private Limited, has been struck off from the Register of Companies effective December 03, 2025. This action is pursuant to sub-section (5) of Section 248 of the Companies Act, 2013. The company received the notice of striking off and dissolution on December 03, 2025. This eliminates the subsidiary from Nureca's consolidated financials.
- Nureca Healthcare Private Limited is a wholly owned subsidiary of Nureca Limited.
- The strike-off is effective from December 03, 2025.
- The action is under sub-section (5) of Section 248 of the Companies Act, 2013.
Nureca Limited has announced a buyback of its equity shares for an aggregate amount not exceeding ₹19,14,00,000. The buyback will be executed through a tender offer via the stock exchange mechanism, in accordance with SEBI regulations and the Companies Act. The maximum buyback price is set at ₹330.00 per equity share, payable in cash. Mefcom Capital Markets Limited has been appointed as the merchant banker to manage the buyback process.
- Buyback size not exceeding ₹19,14,00,000
- Maximum Buyback Price of ₹330.00 per Equity Share
- Face value of ₹ 10/- per equity share
- Buyback approved on November 28, 2025
Financial Performance
Revenue Growth by Segment
The company operates as a digital-first healthcare entity with over 93% of revenue generated through online sales. Standalone revenue from operations grew 21.28% YoY to INR 1,146.40 Mn in FY25 compared to INR 945.21 Mn in FY24. In Q2 FY26, revenue reached INR 528 Mn, representing a 7% YoY growth from INR 493 Mn in Q2 FY25.
Geographic Revenue Split
While specific regional percentages are not disclosed, the company maintains a registered office in Mumbai and a correspondence office in Chandigarh. Sourcing and management activities are indicated in Guangzhou, China, where directors signed financial statements on May 05, 2025.
Profitability Margins
Profitability has shown a significant turnaround. The standalone loss before tax narrowed by 85.9% from INR 32.69 Mn in FY24 to INR 4.60 Mn in FY25. By H1 FY26, the consolidated PAT margin reached 10%, a substantial recovery from the negative margins in previous fiscal years.
EBITDA Margin
The consolidated EBITDA margin stood at 24% for H1 FY26. This reflects a strong recovery in core profitability compared to the -1% EBITDA margin reported in FY24 and 0% in FY25, driven by better cost management and higher sales volumes.
Capital Expenditure
Nureca follows an asset-light business model. Fixed assets were reported at INR 8.3 Crore in H1 FY26, showing a slight increase from INR 4.0 Crore in FY25. This low CAPEX requirement allows the company to remain debt-free while scaling operations.
Credit Rating & Borrowing
The company is debt-free as of H1 FY26. Finance costs for FY25 were INR 11.15 Mn, up from INR 4.60 Mn in FY24, primarily related to lease liabilities or short-term working capital requirements rather than long-term debt.
Operational Drivers
Raw Materials
As an asset-light company, the primary cost is 'Purchase of stock-in-trade' (finished medical and healthcare devices), which accounted for INR 864.89 Mn in FY25, representing 75.4% of total revenue.
Import Sources
The company likely sources finished goods from China, as evidenced by the presence of the Managing Director and CEO in Guangzhou, China, for the signing of the FY25 financial statements.
Key Suppliers
Specific supplier names are not disclosed, but the company relies on third-party manufacturers for its 'Dr Trust' and other branded healthcare products to maintain its asset-light status.
Capacity Expansion
Current capacity is not measured in MT/MW as the company is a digital-first brand aggregator. Expansion is focused on product portfolio breadth rather than manufacturing plants.
Raw Material Costs
Purchase of stock-in-trade increased 36.8% YoY to INR 864.89 Mn in FY25. This cost represents the largest operational outflow, making margins highly sensitive to procurement pricing and import duties.
Manufacturing Efficiency
Efficiency is measured by inventory and debtor management rather than plant utilization. The Debtor Turnover Ratio is highly efficient at 15.3 days in H1 FY26, reflecting the cash-and-carry nature of online retail.
Logistics & Distribution
Distribution is primarily handled through e-commerce marketplaces. Other expenses, which include logistics and marketing, rose 13.4% to INR 303.31 Mn in FY25.
Strategic Growth
Expected Growth Rate
7-21%
Growth Strategy
Growth is driven by a 'Digital First' strategy focusing on high-growth online healthcare segments. The company is optimizing its portfolio by striking off non-performing subsidiaries like Nureca Healthcare Private Limited (Dec 2025) and utilizing a buyback of 5,80,000 shares to improve shareholder value and signal management confidence.
Products & Services
The company sells world-class healthcare solutions including medical devices, wellness products, and advanced technology-integrated healthcare monitors.
Brand Portfolio
Dr Trust is the primary brand mentioned in the corporate vision and investor communications.
New Products/Services
The company is focusing on 'cutting-edge technology' and 'personalized care' solutions, though specific revenue contribution percentages for new launches in FY26 are not itemized.
Market Expansion
The company aims to be a 'global leader in healthcare innovation,' suggesting plans to expand its digital footprint beyond the Indian market into international e-commerce territories.
Strategic Alliances
No specific JVs or partner names were disclosed in the provided documents for the FY25-26 period.
External Factors
Industry Trends
The home healthcare industry is growing rapidly due to increased health awareness. Nureca is positioned as a digital-first mover, benefiting from the shift from traditional retail to online healthcare shopping.
Competitive Landscape
The company competes with both traditional medical device manufacturers and new-age D2C wellness brands in the digital space.
Competitive Moat
The moat is built on brand equity (Dr Trust) and a lean, asset-light distribution model. This is sustainable as long as the company maintains high quality-control standards and high ratings on e-commerce platforms.
Macro Economic Sensitivity
Highly sensitive to consumer discretionary spending and healthcare inflation. A slowdown in urban consumption would directly impact the demand for premium home-healthcare devices.
Consumer Behavior
There is a visible shift toward proactive health monitoring at home, which supports the company's core product categories like blood pressure and glucose monitors.
Geopolitical Risks
Trade barriers or import restrictions on medical electronics from China could significantly disrupt the supply chain, as key management operates from Guangzhou.
Regulatory & Governance
Industry Regulations
Operations are subject to CDSCO (Central Drugs Standard Control Organisation) standards for medical devices and Legal Metrology rules for packaged commodities.
Environmental Compliance
ESG compliance costs are not specifically itemized in the financial statements.
Taxation Policy Impact
The company reported a standalone tax expense of zero for FY25 due to the loss before tax of INR 4.60 Mn.
Legal Contingencies
The auditors noted no instances of significant fraud. There are no specific high-value pending court cases or tribunal disputes mentioned in the provided financial summaries.
Risk Analysis
Key Uncertainties
The primary uncertainty is the sustainability of high margins if competition intensifies on major e-commerce platforms, potentially impacting margins by 5-10%.
Geographic Concentration Risk
Revenue is concentrated in the Indian market via online channels, while the supply chain is concentrated in China.
Third Party Dependencies
High dependency on third-party logistics and e-commerce platforms for the delivery of products to end customers.
Technology Obsolescence Risk
The company faces the risk of rapid technological changes in medical sensors; failure to upgrade the 'Dr Trust' app or device tech could lead to market share loss.
Credit & Counterparty Risk
Credit risk is low as evidenced by the Debtor Turnover Ratio of 15.3 days, indicating that most sales are prepaid or settled quickly by marketplaces.